Porfire Alina, Filip Cristina, Tomuta Ioan
Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.
Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.
J Pharm Biomed Anal. 2017 May 10;138:1-13. doi: 10.1016/j.jpba.2017.01.030. Epub 2017 Jan 19.
The aim of this study was the development and validation of methods based on near-infrared spectroscopy (NIRS) and chemometry, useful for characterization of sustained release (SR) tablets with indapamide, in terms of tablet composition (API and two excipients), in vitro drug release mechanism (k and n Peppas) and crushing strength. A calibration set consisting of 25 different tablets formulations containing API, HPMC and lactose at five different content levels in the range 100±20% relative to a targeted tablet composition, were manufactured by direct compression in order to develop the methods for prediction of tablet composition, and in vitro drug release mechanism. On the other hand, a 15 batches calibration set prepared at five different compression forces was used for development of methods for prediction of crushing strength. Moreover, independent batches were manufactured for validation of all methods Intact tablets were analyzed by transmission mode with NIRS, the spectra were pre-processed, and partial least square (PLS) regression was used to build prediction models. Cross-validation was carried out in order to select the optimal number of PLS factors for all models, and the best model was chosen based on their RMSECV and bias. All developed methods were validated in terms of trueness, precision and accuracy. Based on the validation results, the methods proposed in this work can successfully be applied for routine determination of indapamide, HPMC and lactose content of sustained release tablets, as well as for prediction of their in vitro drug release mechanism (k and n Peppas) and crushing strength.
本研究的目的是开发并验证基于近红外光谱(NIRS)和化学计量学的方法,这些方法可用于表征含有吲达帕胺的缓释(SR)片剂,涉及片剂组成(活性成分和两种辅料)、体外药物释放机制(k和n,佩帕斯模型)以及抗压强度。制备了一个校准集,其中包含25种不同的片剂配方,这些配方含有活性成分、羟丙甲纤维素(HPMC)和乳糖,相对于目标片剂组成,其含量在五个不同水平,范围为100±20%,通过直接压片法制备这些片剂,以开发预测片剂组成和体外药物释放机制的方法。另一方面,制备了一个由15批样品组成的校准集,这些样品在五个不同的压力下压制而成,用于开发预测抗压强度的方法。此外,还制备了独立批次的样品用于所有方法的验证。完整的片剂通过NIRS透射模式进行分析,对光谱进行预处理,并使用偏最小二乘(PLS)回归建立预测模型。进行交叉验证以选择所有模型的最佳PLS因子数量,并根据均方根误差交叉验证值(RMSECV)和偏差选择最佳模型。所有开发的方法均在准确性、精密度和正确度方面进行了验证。基于验证结果,本研究中提出的方法可成功应用于常规测定缓释片剂中吲达帕胺、HPMC和乳糖的含量,以及预测其体外药物释放机制(k和n,佩帕斯模型)和抗压强度。